79.31
price down icon0.81%   -0.65
after-market After Hours: 79.40 0.09 +0.11%
loading
Merck Co Inc stock is traded at $79.31, with a volume of 11.57M. It is down -0.81% in the last 24 hours and up +0.32% over the past month. Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$79.96
Open:
$80.155
24h Volume:
11.57M
Relative Volume:
0.75
Market Cap:
$199.15B
Revenue:
$63.92B
Net Income/Loss:
$17.43B
P/E Ratio:
11.54
EPS:
6.87
Net Cash Flow:
$17.04B
1W Performance:
-5.21%
1M Performance:
+0.32%
6M Performance:
-17.59%
1Y Performance:
-36.94%
1-Day Range:
Value
$78.95
$80.31
1-Week Range:
Value
$78.95
$84.36
52-Week Range:
Value
$73.31
$128.73

Merck Co Inc Stock (MRK) Company Profile

Name
Name
Merck Co Inc
Name
Phone
908-740-4000
Name
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Name
Employee
75,000
Name
Twitter
@Merck
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
MRK's Discussions on Twitter

Compare MRK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
MRK
Merck Co Inc
79.31 210.10B 63.92B 17.43B 17.04B 6.87
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.18 717.60B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.36 377.32B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.85 338.30B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.14 234.32B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.92 306.33B 43.59B 15.04B 10.74B 3.3766

Merck Co Inc Stock (MRK) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Feb-18-25 Downgrade Deutsche Bank Buy → Hold
Feb-10-25 Downgrade TD Cowen Buy → Hold
Jan-08-25 Downgrade Truist Buy → Hold
Dec-20-24 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-10-24 Resumed BofA Securities Buy
Dec-04-24 Upgrade HSBC Securities Hold → Buy
Nov-15-24 Initiated Wolfe Research Peer Perform
Nov-11-24 Downgrade Daiwa Securities Buy → Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Mar-11-24 Downgrade Societe Generale Hold → Sell
Jan-04-24 Upgrade TD Cowen Market Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Buy
Oct-27-23 Upgrade BMO Capital Markets Market Perform → Outperform
Oct-20-23 Upgrade UBS Neutral → Buy
Jul-14-23 Initiated HSBC Securities Hold
Apr-13-23 Upgrade Citigroup Neutral → Buy
Mar-28-23 Downgrade Societe Generale Buy → Hold
Mar-13-23 Downgrade Wells Fargo Overweight → Equal Weight
Mar-06-23 Initiated Jefferies Buy
Feb-22-23 Upgrade Wolfe Research Peer Perform → Outperform
Jan-04-23 Upgrade BofA Securities Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
Oct-10-22 Upgrade Guggenheim Neutral → Buy
Sep-14-22 Upgrade Berenberg Hold → Buy
Jul-06-22 Upgrade Daiwa Securities Neutral → Buy
Jun-06-22 Resumed SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Dec-17-21 Initiated Goldman Buy
Dec-16-21 Initiated Daiwa Securities Neutral
Dec-13-21 Downgrade UBS Buy → Neutral
Dec-09-21 Initiated Wells Fargo Overweight
Dec-07-21 Downgrade Guggenheim Buy → Neutral
Nov-29-21 Downgrade Citigroup Buy → Neutral
Nov-19-21 Initiated BMO Capital Markets Market Perform
Nov-01-21 Upgrade Argus Hold → Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-27-21 Resumed Truist Buy
May-20-21 Downgrade Argus Buy → Hold
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Aug-03-20 Upgrade Goldman Neutral → Buy
Jun-12-20 Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20 Initiated Barclays Overweight
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Oct-17-19 Resumed BofA/Merrill Neutral
Aug-16-19 Initiated SVB Leerink Outperform
Jul-03-19 Initiated Mizuho Buy
May-28-19 Initiated Goldman Neutral
May-13-19 Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18 Reiterated Citigroup Buy
Oct-09-18 Resumed Guggenheim Buy
Apr-23-18 Upgrade Goldman Neutral → Buy
Apr-17-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18 Upgrade Barclays Equal Weight → Overweight
Mar-12-18 Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18 Reiterated Leerink Partners Mkt Perform
Feb-07-18 Reiterated Morgan Stanley Equal-Weight
Jan-16-18 Upgrade SunTrust Hold → Buy
View All

Merck Co Inc Stock (MRK) Latest News

pulisher
06:31 AM

Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production - Insider Monkey

06:31 AM
pulisher
10:00 AM

Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times

10:00 AM
pulisher
Jul 20, 2025

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - The Motley Fool

Jul 20, 2025
pulisher
Jul 19, 2025

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jul 19, 2025
pulisher
Jul 18, 2025

Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Merck KGaA gets EU nod for Ezmekly (MRK:NYSE) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges By Investing.com - Investing.com UK

Jul 18, 2025
pulisher
Jul 16, 2025

Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 15, 2025

Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill - Business Wire

Jul 14, 2025
pulisher
Jul 13, 2025

Verona Pharma (VRNA) Opinions on Merck Acquisition News - Quiver Quantitative

Jul 13, 2025
pulisher
Jul 12, 2025

Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more - Seeking Alpha

Jul 12, 2025
pulisher
Jul 12, 2025

Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition - Yahoo Finance

Jul 12, 2025
pulisher
Jul 11, 2025

Success Tricking FDA Shouldn't Protect Merck, Justices Told - Law360

Jul 11, 2025
pulisher
Jul 11, 2025

Merck to Acquire Verona Pharma in $10B Bid - USA Herald

Jul 11, 2025
pulisher
Jul 11, 2025

Top Analyst Reports for Microsoft, Alibaba & Merck - TradingView

Jul 11, 2025
pulisher
Jul 11, 2025

FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Yahoo Finance

Jul 11, 2025
pulisher
Jul 11, 2025

With Verona deal, Merck wagers on strength of lung drug’s patents - BioPharma Dive

Jul 11, 2025
pulisher
Jul 11, 2025

Merck: Jefferies raises TP after Verona acquisition - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? - Nasdaq

Jul 11, 2025
pulisher
Jul 10, 2025

Merck Animal Health gets FDA nod for Bravecto Quantum (MRK:NYSE) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Merck Animal Health's Flea-and-Tick Treatment Approved in U.S. - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Business Wire

Jul 10, 2025
pulisher
Jul 10, 2025

Merck & Co. Remains In The BD Game After Verona Takeout - insights.citeline.com

Jul 10, 2025
pulisher
Jul 10, 2025

Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration - Insider Monkey

Jul 10, 2025
pulisher
Jul 10, 2025

Merck's doravirine/islatravir under FDA review for HIV (MRK:NYSE) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire

Jul 10, 2025
pulisher
Jul 10, 2025

Merck to acquire UK drugmaker Verona Pharma for $10bn - World Pharmaceutical Frontiers

Jul 10, 2025
pulisher
Jul 10, 2025

Foley Represents Verona Pharma in $10B Acquisition by Merck - Foley & Lardner LLP

Jul 10, 2025
pulisher
Jul 09, 2025

Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory - insights.citeline.com

Jul 09, 2025
pulisher
Jul 09, 2025

In a $10B deal, Merck buys cardio developer Verona - BioWorld MedTech

Jul 09, 2025
pulisher
Jul 09, 2025

Merck spends $10 billion for Verona, gaining access to its COPD medication - Jacksonville Journal-Courier

Jul 09, 2025
pulisher
Jul 09, 2025

Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue (NYSE:MRK) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to buy Verona and its lung drug in $10B deal - BioPharma Dive

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to Buy Verona Pharma in $10 Billion Deal - The Wall Street Journal

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to acquire Verona Pharma for $10 billion - Reuters

Jul 09, 2025
pulisher
Jul 09, 2025

Verona Pharma Stock Jumps 20%. It’s Being Bought for $10 Billion by Merck. - Barron's

Jul 09, 2025
pulisher
Jul 09, 2025

Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B - Investopedia

Jul 09, 2025

Merck Co Inc Stock (MRK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general NVO
$64.92
price up icon 0.95%
$295.87
price up icon 0.38%
drug_manufacturers_general NVS
$114.14
price down icon 0.10%
drug_manufacturers_general PFE
$24.26
price down icon 0.86%
$108.28
price up icon 0.06%
Cap:     |  Volume (24h):